Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068)

E. J. Shpall, R. E. Champlin, A. C. Eaves, A. P. Gee, N. Collins, C. F. LeMaistre, R. O'Reilly, S. D. Rowley, K. Sullivan, W. P. Vaughan, P. L. Warkentin

Research output: Contribution to journalShort survey

Abstract

We believe the proposed model is appropriate to our current state of knowledge and recognize that FDA regulations will evolve as the field evolves. We thank you for the opportunity to work with FDA as its regulatory strategy is developed in the near future.

Original languageEnglish (US)
Pages (from-to)287-289
Number of pages3
JournalJournal of hematotherapy
Volume6
Issue number4
DOIs
StatePublished - Jan 1 1997

ASJC Scopus subject areas

  • Immunology
  • Hematology

Fingerprint Dive into the research topics of 'Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068)'. Together they form a unique fingerprint.

  • Cite this

    Shpall, E. J., Champlin, R. E., Eaves, A. C., Gee, A. P., Collins, N., LeMaistre, C. F., O'Reilly, R., Rowley, S. D., Sullivan, K., Vaughan, W. P., & Warkentin, P. L. (1997). Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068). Journal of hematotherapy, 6(4), 287-289. https://doi.org/10.1089/scd.1.1997.6.287